Macquarie expects this ASX All Ords healthcare stock to fall 21% in FY26

The company faces several headwinds across multiple divisions.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As we tick over into FY26, all eyes are focused on stocks offering strong potential gains or losses over the next 12 months.

At the close of FY25 yesterday, leading winners were healthcare stocks. The S&P/ASX 200 Healthcare Index (ASX: XHJ), jumped 1.58% on Monday, and is up 0.27% as of lunchtime today.

Health insurance provider NIB Holdings Ltd (ASX: NHF) was Monday's best index performer. NIB shares had an exceptional start to the week, shooting 9.43% higher to close at $7.08 per share. The increase followed an optimistic report from ASX broker UBS.

But in its latest note to investors, Macquarie Group appears to hold a different view on the stock.

Today the health insurer's share price has corrected by around 2.26%, falling to $6.92 as of lunchtime.

NIB's share price has had a rollercoaster ride over the past year, rising 25.36% since early January. But the stock suffered a sharp 17.74% drop in late August last year after following its full-year results announcement. Over the year, shares are currently 4.55% lower.

For context, the S&P/ASX All Ordinaries Index (ASX: XAO) is 0.14% higher as of lunchtime today.

Here's what Macquarie has to say about NIB in FY26.

shadow of a man looking out a window with arrows signifying falling share price

Image source: Getty Images

Macquarie less confident about NIB shares

The broker has maintained its underperform rating on NIB shares. It cited a cautious outlook off the back of the company's operational and environmental headwinds across multiple divisions.

It has revised its target price on the stock to $5.60, up from $5.55 previously. This would represent a 20.9% decline from yesterday's close and a 19.07% drop from the current trading price.

The broker also expects company earnings to be 1.8% higher for FY25. But, for FY26 it expects a 3.6% decline due to divisional challenges.

In its investor note, Macquarie explained that political and regulatory risk will grow in FY26 as the health minister is given a second term and the NDIS moves into focus.

The broker said it has not included concerns around industry reform into its earning forecast at this stage.

However, it has forecast slight earnings pressure for the company's IIHI (International Inbound Health Insurance) division in FY26. This is largely due to migration trends slow for students, contract pricing comes under pressure, and competition increases across products.

In NIB's New Zealand division, Macquarie notes that while it expects underlying profit to be mostly positive in FY26, appointment of a new division head could create some downside earnings risk for the division. 

"Reshuffling of divisional executives often lead to changes in strategy and earnings rebasing," the note said.

The broker is also keeping a close eye on phoenixing, changes to the price approval process, change to the students deed, and findings of the PALM review. All of these issues could create potential headwinds for the healthcare stock.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor analysing x-rays.
Healthcare Shares

4DMedical shares are rocketing 11% today. Is a short squeeze starting?

Short sellers may be feeling the heat after this week’s rally.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Shares surge as ASX biotech charts road to redemption

A recent major setback might not be so bad.

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development.
Healthcare Shares

Forget CSL shares, I'd buy this ASX biotech stock instead

Brokers tip this other ASX biotech stock to climb up to 76% higher.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

CSL acknowledges "disappointing" results but aims to do better

The search for a new CEO also goes on.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

This sector is coming back into favour.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

4DMedical vs Telix Pharmaceuticals: ASX health tech share showdown

4DMedical and Telix are both Aussie health innovators—here’s which ASX share gets my vote in this biotech battle.

Read more »

cochlear happy, share price rise, up, increase
Healthcare Shares

Cochlear share price rebounds 53% from 10-year low: Can it keep climbing?

The shares are still down 47% for the year to date.

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

Two broker upgrades put CSL shares back in focus

CSL is back on the radar after two broker upgrades.

Read more »